| Literature DB >> 29785504 |
Laurent Jadot1, Luc Huyghens2, Annick De Jaeger3, Marc Bourgeois4, Dominique Biarent5, Adeline Higuet6, Koen de Decker7, Margot Vander Laenen8, Baudewijn Oosterlynck4, Patrick Ferdinande9, Pascal Reper10,11, Serge Brimioulle12, Sophie Van Cromphaut13, Stéphane Clement De Clety14, Thierry Sottiaux15, Pierre Damas16.
Abstract
BACKGROUND: In order to decrease the incidence of ventilator-associated pneumonia (VAP) in Belgium, a national campaign for implementing a VAP bundle involving assessment of sedation, cuff pressure control, oral care with chlorhexidine and semirecumbent position, was launched in 2011-2012. This report will document the impact of this campaign.Entities:
Keywords: Belgian ICUs; VAP; VAP bundle; VAP survey
Year: 2018 PMID: 29785504 PMCID: PMC5962527 DOI: 10.1186/s13613-018-0412-8
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 6.925
Fig. 1Evolution of the number of ICU beds, patients and ventilated patients in participating ICUs
Characteristics of ventilated patients
| Characteristics of patients | |||||||
|---|---|---|---|---|---|---|---|
| 2010 | 2011 | 2013 | 2014 | 2015 | 2016 | ||
| Number | 129 | 293 | 288 | 265 | 271 | 158 | |
| Age median (IQR) | 67 (54–78) | 65 (54–75) | 66 (54–75) | 67 (57–76) | 64 (54–76) | 64 (50–71) | 0.8412 |
| Sex (male) | 88 (68.8%) | 183 (62.5%) | 183 (63.5%) | 162 (61.1%) | 170 (62.7%) | 102 (64.6%) | 0.8326 |
| Pre-ICU hosp. stay | 0 (0–4) | 0 (0–2) | 0 (0–2) | 1 (0–5) | 0 (0–2) | 0 (0–2) | 0.3229 |
| ICU stay median | 10 (4–19) | 13 (7–21) | 8 (3–18) | 7 (2–16) | 7 (2–16) | 8 (2–19) | < 0.0001 |
| Duration of ventilation median | 10.5 (4–17) | 13 (7–21) | 7 (3–16) | 5 (2–14) | 5 (1–15) | 6 (2–14) | < 0.0001 |
|
| 0.0655 | ||||||
| Medical | 71 (55.8%) | 156 (53.2%) | 155 (53.2%) | 138 (52.1%) | 153 (56.5%) | 94 (59.4%) | |
| Scheduled surgery | 12 (9.3%) | 51 (17.4%) | 57 (19.8%) | 52 (19.6%) | 45 (16.6%) | 18 (11.4%) | |
| Nonscheduled surgery | 32 (24.8%) | 51 (17.4%) | 48 (16.7%) | 59 (22.3%) | 42 (15.5%) | 30 (19%) | |
| Trauma | 13 (10.1%) | 35 (16.1%) | 28 (9.7%) | 16 (6%) | 31 (11.4%) | 16 (10.1%) | |
|
| 0.2724 | ||||||
| Smoker | 44 (34.1%) | 102 (47%) | 103 (35.7% | 75 (28.3%) | 81 (29.9%) | 51 (32.3%) | |
| Asthma | 7 (5.4%) | 13 (4.4%) | 5 (1.7%) | 19 (7.2%) | 9(3.3%) | 5 (3.2%) | |
| COPD | 36 (27.9%) | 83 (28.3%) | 89 (30.9%) | 63 (23.8%) | 64 (23.6%) | 38 (24%) | |
| Solid cancer | 4 (3.1%) | 36 (12.3%) | 28 (9.7%) | 28 (10.6%) | 20 (7.4%) | 12 (7.6%) | |
| Hematological cancer | 7 (5.4%) | 7 (2.4%) | 10 (3.5%) | 4 (1.5%) | 9 (3.3%) | 4 (2.5%) | |
| Immunosuppression | 12 (9.3%) | 25 (8.5%) | 20 (6.9%) | 19 (7.2%) | 16 (5.9%) | 6 (3.8%) | |
| Corticotherapy | 9 (7%) | 37 (12.6%) | 28 (9.7%) | 39 (14.7%) | 27 (10%) | 15 (9.5%) | |
| Diabetes | 13 (10.1%) | 38 (13%) | 42 (14.6%) | 34 (12.8%) | 34 (12.5%) | 17 (10.8%) | |
| Other | NA | NA | NA | 26 (9.8%) | 26 (9.6%) | 75 (47.4%) | |
|
| 0.0012 | ||||||
| Hypoxia | 50 (38.8%) | 79 (27%) | 95 (33%) | 83 (31.3%) | 80 (29.5%) | 55 (34.8%) | |
| Hypercapnia | 7 (5.4%) | 39 (13.3%) | 24 (8.3%) | 19 (7.2%) | 11 (4.1%) | 16 (10.1%) | |
| Central nervous system | 24 (18.6%) | 47 (16%) | 40 (13.9%) | 32 (12.1%) | 45 (16.6%) | 19 (12%) | |
| Peripheral nervous system | 0 (0%) | 1 (0.3%) | 2 (0.7%) | 4 (1.5%) | 5 (1.8%) | 2 (1.3%) | |
| Trauma | 7 (5.4%) | 14 (4.8%) | 12 (4.2%) | 9 (3.4%) | 14 (5.2%) | 10 (6.3%) | |
| Circulatory problem | 17 (13.2%) | 38 (13%) | 40 (17.4%) | 40 (15.1%) | 43 (15.9%) | 17 (10.8%) | |
| Postoperative | 17 (13.2%) | 30 (10.2%) | 59 (20.5%) | 67 (25.2%) | 63 (23.2%) | 25 (15.8%) | |
| Other | 7 (5.4%) | 13 (1.1%) | 16 (5.6%) | 11 (4.1%) | 10 (3.7%) | 14 (8.9%) | |
IQR Interquartile range, ICU intensive care unit, COPD chronic obstruction pulmonary disease, NA not available
Ventilatory care
| 2010 | 2011 | 2013 | 2014 | 2015 | 2016 | ||
|---|---|---|---|---|---|---|---|
| Previous NIV | 25 (19.4%) | 50 (17.1%) | 52 (18%) | 46 (17.4%) | 44 (16.2%) | 33 (20.9%) | 0.8685 |
|
| 0.0663 | ||||||
| Oral intubation | 95 (75.4%) | 244 (83.3%) | 234 (81.2%) | 222 (83.8%) | 226 (83.4%) | 132 (83.5%) | |
| Nasal intubation | 0 | 2 (0.7%) | 4 (1.4%) | 4 (1.6%) | 6 (2.2%) | 2 (1.3%) | |
| Tracheostomy | 34 (26.4%) | 47 (16%) | 50 (17.4%) | 39 (14.7%) | 39 (14.4%) | 24 (15.2%) | |
|
| 0.0318 | ||||||
| Polyvinyl | 74 (64.3%) | 166 (56.6%) | 170 (59%) | 143 (54%) | 158 (58.3%) | 110 (69.6%) | |
| Polyurethane | 41 (36.7%) | 127 (43.3%) | 118 (41%) | 122 (46%) | 113 (41.7%) | 48 (30.4%) | |
|
| < 0.0001 | ||||||
| Not measured | 9 (7%) | 72 (24.6%) | 2 (0.7%) | 10 (3.8%) | 4 (1.5%) | 6 (3.8%) | |
| < 20 cm H2O | 25 (19.4%) | 18 (6.1%) | 9 (3.1%) | 9 (3.4%) | 2 (0.7%) | 7 (4.4%) | |
| 20–30 cm H2O | 91 (70.5%) | 196 (66.9%) | 263 (91%) | 228 (86%) | 251 (92.6%) | 137 (86.7%) | |
| > 30 cm H2O | 4 (3.1%) | 6 (2%) | 10 (3.5%) | 15 (5.7%) | 10 (3.7%) | 5 (3.2%) | |
| Not inflated | 0 | 1 (0.3%) | 4 (1.4%) | 3 (1.1%) | (1.5%) | 3 (1.9%) | |
|
| < 0.0001 | ||||||
| Opened | 76 (62.8%) | 236 (80.5%) | 204 (70.8%) | 171 (64.5%) | 205 (75.6%) | 120 (79.7%) | |
| Closed | 45 (37.2%) | 57 (19.5%) | 84 (29.2%) | 94 (35.5%) | 66 (24.4%) | 38 (20.3%) | |
|
| < 0.0001 | ||||||
| Yes | 7 (5.8%) | 67 (22.9%) | 94 (32.6%) | 60 (22.6%) | 70 (25.8%) | 39 (24.7%) | |
| No | 114 (94.2%) | 226 (77.1%) | 194 (69.2%) | 205 (77.4%) | 201 (74.2%) | 119 (75.3%) | |
|
| < 0.0001 | ||||||
| < 30° | 55 (44.4%) | 43 (14.7%) | 21 (7.3%) | 13 (4.9%) | 25 (9.2%) | 18 (11.4%) | |
| > 30° | 67 (54.0%) | 249 (85%) | 262 (91%) | 249 (94%) | 245 (90.4%) | 140 (88.6%) | |
| Prone position | 2 (1.6%) | 1 (0.3%) | 5 (1.7%) | 3 (1.1%) | 1 (3.7%) | 0 (0%) |
NIV Noninvasive ventilation
Oral care
| Oral disinfection | 2010 | 2011 | 2013 | 2014 | 2015 | 2016 | |
|---|---|---|---|---|---|---|---|
| Water | 1 (1%) | 6 (2%) | 1 (0.3%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| CHXD 0.2% | 48 (38.4%) | 126 (43%) | 108 (37.5%) | 132 (49.8%) | 90 (33.2%) | 79 (50%) | < 0.0001 |
| CHXD 0.5% | 13 (10.4%) | 5 (1.7%) | 11 (3.8%) | 7 (2.6%) | 4 (1.5%) | 5 (3.2%) | |
| CHXD 1% | 0 (0%) | 2 (0.7%) | 26 (9%) | 7 (2.6%) | 16 (5.9%) | 3 (1.9%) | |
| CHXD 2% | 0 (0%) | 0 (0%) | 10 (3.5%) | 9 (3.4%) | 15 (5.5%) | 7 (4.4%) | |
| Polyvidone iodine | 44 (35.2%) | 119 (40.6%) | 102 (35.4%) | 93 (35.1%) | 124 (45.8%) | 55 (34.8%) | |
| Other | 19 (15.2%) | 35 (11.9%) | 30 (10.4%) | 17 (6.4%) | 22 (8.11%) | 10 (6.3%) | |
|
| |||||||
| 1/day | 2 (1.6%) | 31 (10.6%) | 3 (1%) | 9 (3.4%) | 2 (0.7%) | 0 (0%) | < 0.0001 |
| 2/day | 24 (19.2%) | 41 (14%) | 24 (8.3%) | 27 (10.2%) | 22 (8.1%) | 8 (5.1%) | |
| 3/day | 36 (28.8%) | 117 (39.9%) | 158 (54.9%) | 136 (51.3%) | 116 (42.8%) | 75 (47.4%) | |
| > 3/day | 63 (50.4%) | 104 (35.5%) | 103 (35.8%) | 93 (35.1%) | 131 (48.3%) | 75 (47.4%) | |
|
| |||||||
| 0/day | NK | 63 (21.5%) | 51 (18.7%) | 32 (12.9%) | 36 (13.3%) | 27 (17.1%) | 0.0235 |
| 1/day | NK | 99 (33.8%) | 103 (35.8%) | 88 (33.3%) | 83 (30.6%) | 63 (39.9%) | |
| 2/day | NK | 70 (23.9%) | 63 (21.9%) | 81 (38.6%) | 84 (31%) | 51 (32.3%) | |
| 2/day | NK | 46 (15.7%) | 47 (16.3%) | 45 (17%) | 53 (19.6%) | 11 (7%) | |
| Not applicable | NK | 15 (5.1%) | 25 (8.7%) | 19 (7.2%) | 15 (5.5%) | 6 (3.8%) |
CHXD Chlorhexidine, NK: not known
Fig. 2Percentage of ventilated patients treated for VAP the day of the survey